Turning Point Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a TPTX research report →
About the company
Turning Point Therapeutics is a biopharmaceutical firm specializing in precision oncology, currently in the clinical development stage. The company is dedicated to discovering and advancing targeted therapies that address the underlying genetic causes of cancer. They have developed a portfolio of innovative tyrosine kinase inhibitors (TKIs) designed to treat cancer patients, including those who have not yet received TKI treatment and those who have previously been treated with TKIs.
- CEO
- Athena Maria Countouriotis
- IPO
- 2019
- Employees
- 267
- HQ
- San Diego, CA, US
Price Chart
- Market Cap
- $0
- P/E
- -13.04
- P/S
- 0.00
- P/B
- 3.23
- EV/EBITDA
- 1.82
- Div Yield
- 0.00%
- Gross Margin
- 100.00%
- Op Margin
- -767.30%
- Net Margin
- -767.30%
- ROE
- -22.92%
- ROIC
- -24.64%
- Revenue
- $30.83M · 23.32%
- Net Income
- $-236,551,000 · -50.39%
- EPS
- $-5.79 · -50.39%
- Op Income
- $-236,551,000
- FCF YoY
- -85.96%
- Beta
- -0.19
Get TickerSpark's AI analysis on TPTX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 17, 22 | Nicholson Garry A | sell | 23,400 |
| Aug 17, 22 | Nicholson Garry A | sell | 8,500 |
| Aug 17, 22 | Nicholson Garry A | sell | 8,500 |
| Aug 17, 22 | Machado Patrick | sell | 30,000 |
| Aug 17, 22 | George Simeon | sell | 8,500 |
| Aug 17, 22 | Gallagher Carol Giltner | sell | 8,500 |
| Aug 17, 22 | Gallagher Carol Giltner | sell | 30,000 |
| Aug 17, 22 | Gallagher Carol Giltner | sell | 8,500 |
| Aug 17, 22 | Gallagher Carol Giltner | sell | 8,500 |
| Aug 17, 22 | Bodem Barbara W. | sell | 14,995 |
Our TPTX coverage
Recent articles, reports, and earnings notes.
No research on TPTX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate TPTX report →Similar companies
Peers in the same neighborhood.